Fig. 1 · Structure

Documents & Downloads

Ro 31-8220 mesylate

Cat. No. A13514 CAS 138489-18-6

PKC inhibitor

Ro 31-8220 mesylate is a PKC-inhibitor, which inhibits stimulated fluid pinocytosis of human PMNs induced by the PKC-activators phorbol myristate acetate (PMA, IC50 = 1.35 x 10(-6) M) or diacylglycerols (OAG, diC8) by 95%.

In Stock

Publications for Ro 31-8220 mesylate

1 publication citing this product

  1. Dao-Lai Zhang, .et al. , eLife, 2018, 7: e33432 PMID: 29393851

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
PKCα 5 nM
PKCβ2 14 nM
PKCβ1 24 nM
PKCε 24 nM
PKCγ 27 nM

Ro 31-8220 mesylate Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Ro 31-8220 mesylate from 3 published references. In vitro models include KB Telo MyoD cells.

Ro 31-8220 mesylate In Vitro Studies

In cardiomyocytes, Ro 31-8220 decreased PKC-α expression and activity compared with cardiomyocytes cultured in high glucose. In cells, treatment produced significant redistribution of COPI coatomer staining as early as 5 min after treatment. In KB Telo MyoD cells (DM1), treatment resulted in a 91% reduction in CELF1 protein compared with DMSO. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

PKC-α expression and activity in cardiomyocytes

Cell-based study · cardiomyocytes; n = 4 or 5 [1]

Cardiomyocytes were treated with Ro 31-8220 at 50 nmol/L for 48 hours. Compared with cardiomyocytes cultured in high glucose, treatment decreased PKC-α expression and activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
the expression and activity of PKC-αReported result the expression and activity of PKC-α decreased[1]

Literature-Reported Treatment Conditions

Treatment concentration
50 nmol/L
Exposure duration
48 hours
Method
adding PKC inhibitor Ro-31-8220
Co-treatment
Other interventions in this design: glucose 25.5 mmol/L; 5-Bru 0.1 mmol/L. Compound effect isolated by the comparison: compared with the cardiomyocytes cultured in high glucose levels.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Ro 31-8220

The paper names Ro 31-8220 without stating the salt or form; not verified as the mesylate form supplied as A13514. No dose conversion or lot validation.

Methods > 2. Methods > 2.1 Culture of neonatal rat ventricular myocytes (S11); Results > 3.3 Effect of high glucose and PKC inhibitor Ro-31-8220 on the expression and activity of PKC in cardiomyocytes (S35, S36, S38); Figure 1 legend (S57, S59)

the expression and activity of PKC-α: the expression and activity of PKC-α; comparator: high glucose (25.5 mmol/L) — Figure 1 legend (S57)

COPI coatomer staining redistribution in cells

Cell-based study · cells [2]

Cells were treated with the compound at 5 μM, with vehicle-treated cells as the control. Significant redistribution of COPI coatomer staining occurred as early as 5 min after treatment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Quantification of the relative numbers of COPI transport carriers using the granularity measurement module in MetaXpress softwareReported result a significant redistribution of COPI coatomer staining as early as 5 min after treatment[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM
Exposure duration
over the indicated times
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Ro 31-8220

The paper names Ro 31-8220 without stating the salt or form; not verified as the mesylate form supplied as A13514. No dose conversion or lot validation.

Results > ERK8 regulates COPI-dependent GalNAc-Ts traffic (S119); Figure 5—figure supplement 1. legend (S348, S349, S353)

Quantification of the relative numbers of COPI transport carriers using the granularity measurement module in MetaXpress software: Quantification of the relative numbers of COPI transport carriers using the granularity measurement module in MetaXpress software; comparator: vehicle treated — Results > ERK8 regulates COPI-dependent GalNAc-Ts traffic (S119); Figure 5—figure supplement 1. legend (S349)

CELF1 protein reduction in KB Telo MyoD cells

Cell-based study · KB Telo MyoD cells (DM1) [3]

KB Telo MyoD cells (DM1) were treated with Ro 31-8220 at 10 μm. Compared with DMSO, treatment resulted in a 91% reduction in CELF1 protein normalized against α-tubulin levels.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
quantification of CELF1 protein normalized against α-tubulin levelsCELF1 protein levels 91% reduction in CELF1 protein[3]

Literature-Reported Treatment Conditions

Treatment concentration
10 μm
Co-treatment
Other interventions in this design: an engineered lentivirus. Compound effect isolated by the comparison: DMSO.
Reported limits
Not stated in the sentences used: route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: Ro 31-8220

The paper names Ro 31-8220 without stating the salt or form; not verified as the mesylate form supplied as A13514. No dose conversion or lot validation.

RESULTS > Primary screen for compounds that remove nuclear foci (S3); RESULTS > The effect of compounds on foci is not mediated by PKC (S124, S132, S133)

quantification of CELF1 protein normalized against α-tubulin levels: quantification of CELF1 protein normalized against α-tubulin levels; comparator: DMSO — RESULTS > The effect of compounds on foci is not mediated by PKC (S124, S133)

Ro 31-8220 mesylate In Vivo Studies

Uninjected control embryos received treatment at 5 μm added directly to the fish water. Treatment had a very mild negative effect on the phenotype, with average somite number 10% lower than in untreated embryos. [3]

Somite phenotype in uninjected control embryos

Animal study · Uninjected control embryos [3]

Uninjected control embryos received treatment at 5 μm added directly to the fish water. Treatment had a very mild negative effect on the phenotype, with average somite number 10% lower than in untreated embryos.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
number of somites observed beyond the yolk cell extensionaverage somite number average somite number being 10% lower than untreated embryos[3]

Conditions shared by the study groups

Route
added directly to the fish water
Treatment course
at 2 hpf; for 24 h
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ro 31-8220 5 μmuntreated embryosa very mild negative effect on the phenotype of these embryos with the average somite number being 10% lower than untreated embryos[3]
Ro 31-8220 5 μm
Model: Uninjected control embryos
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Ro 31-8220

The paper names Ro 31-8220 without stating the salt or form; not verified as the mesylate form supplied as A13514. No dose conversion or lot validation.

RESULTS > The effect of compounds in a CUG-repeat expansion zebrafish model (S92, S93, S94); METHODS AND MATERIALS > Zebrafish model of myotonic dystrophy (S169, S170)

number of somites observed beyond the yolk cell extension: number of somites observed beyond the yolk cell extension; comparator: untreated embryos — RESULTS > The effect of compounds in a CUG-repeat expansion zebrafish model (S92, S94)

Ro 31-8220 5 μm · RESULTS > The effect of compounds in a CUG-repeat expansion zebrafish model (S93, S94); METHODS AND MATERIALS > Zebrafish model of myotonic dystrophy (S169, S170)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 138489-18-6
Applications PKC inhibitor
Formula C25H23N5O2S.CH3SO3H
Molecular Weight 553.7
Synonyms BIM IX; Bisindolylmaleimide IX (mesylate)
SMILES
CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)CCCSC(=N)N.CS(=O)(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 85 mg/mL (153.52 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Ro 31-8220 mesylate Research References

  1. [1] Min W, Bin ZW, Quan ZB, et al. The signal transduction pathway of PKC/NF-kappa B/c-fos may be involved in the influence of high glucose on the cardiomyocytes of neonatal rats. Cardiovasc Diabetol (2009). PMID: 19210763 DOI: 10.1186/1475-2840-8-8 Source material
  2. [2] Chia J, Tham KM, Gill DJ, et al. ERK8 is a negative regulator of O-GalNAc glycosylation and cell migration. Elife (2014). PMID: 24618899 DOI: 10.7554/eLife.01828 Source material
  3. [3] Ketley A, Chen CZ, Li X, et al. High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines. Hum Mol Genet (2014). PMID: 24179176 DOI: 10.1093/hmg/ddt542 Source material

Publications

1 publication citing this product

  1. Dao-Lai Zhang, .et al. , eLife, 2018, 7: e33432 PMID: 29393851

Added to your cart

View Cart Checkout
Loading...